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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food
Allergens (NDA) was asked to deliver an opinion on 6′-Sialyllactose (6′-SL) sodium salt as a novel food
(NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk
oligosaccharide (HiMO) 6′-SL but also contains D-lactose, sialic acid and a small fraction of other related
oligosaccharides. The NF is produced by fermentation with a genetically modified strain of Escherichia
coli K-12 DH1. The information provided on the manufacturing process, composition and specifications of
the NF does not raise safety concerns. The applicant intends to add the NF in a variety of foods, including
infant and follow-on formula, foods for infants and toddlers, foods for special medical purposes and food
supplements. The target population is the general population. The anticipated daily intake of 6′-SL from
the NF at the maximum proposed use levels is unlikely to exceed the intake level of naturally occurring
6′-SL in breastfed infants on a body weight basis. The intake of 6′-SL in breastfed infants on a body
weight basis is expected to be safe also for other population groups. The intake of other carbohydrate-
type compounds structurally related to 6′-SL is also considered of no safety concern. Food supplements
are not intended to be used if other foods with the added NF or breast milk are consumed on the same
day. The Panel concludes that the NF is safe under the proposed conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 31 January 2019, the company Glycom A/S submitted a request to the European Commission in
accordance with Article 10 of Regulation (EU) 2015/22831 to place on the EU market 6′-Sialyllactose
(6′-SL) sodium salt as a novel food.
6′-Sialyllactose (6′-SL) sodium salt is intended to be used in a number of food categories.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on 6′-Sialyllactose (6′-SL) sodium salt as
a novel food.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following EFSA requests for supplementary information.
During the assessment, the Panel identified additional data, which were not included in the
application (Goehring et al., 2014; Gorbach, 1978, Rudloff et al., 1996, 2012; Vazquez et al., 2017;
Zeng et al., 2018).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24692.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of an NF application (EFSA NDA Panel, 2016). As
indicated in this guidance, it is the duty of the applicant to provide all available (proprietary,
confidential and published) scientific data, including both data in favour and not in favour to
supporting the safety of the proposed NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include:
• Detailed description of the production process – raw materials and schematic overview of the
processing (sections of the dossier 2.b.1.1-4).
• Annexes to the dossier, which relate to the identity, production process, production
microorganism, composition and specifications of the NF (annex I ‘NMR analytical report’, annex
II ‘production strain data’, annex III ‘production strain certificates’, annex IV ‘raw materials and
processing aids’, annex V ‘certificate of analysis and batch data’, annex VI ‘analytical method
validation report’, annex VII ‘Stability reports’, annex VIII ‘Laboratory accreditation certificates’).
• Intakes assessment report (annex X to the dossier).
• Unpublished toxicological study reports:
– 6′-Sialyllactose sodium salt – Bacterial Reverse Mutation Test (Unpublished Study report
2018a); In vitro Mammalian Cell Micronucleus Test (Unpublished Study report 2018b); 14-
Day Toxicity Study in the Neonatal Rat (Unpublished Study report, 2018c); 90-Day Toxicity
Study in the Neonatal Rat (Unpublished Study report, 2018d)
– 3′-Sialyllactose sodium salt – Bacterial Reverse Mutation Test (Unpublished study report,
2019a); In vitro Mammalian Cell Micronucleus Test (Unpublished study report, 2019b); 14-
Day Toxicity Study in the Neonatal Rat (Unpublished study report, 2019c); 90-Day Toxicity
Study in the Neonatal Rat (Unpublished study report, 2019d)
• Appendix B.3 to the dossier referring to the summary table of statistically significant
observations in toxicity studies with 6′-Sialyllactose.
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) N0 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA
NDA Panel, 2016) and the principles described in the relevant existing guidance documents from
the EFSA Scientific Committee. The legal provisions for the assessment are laid down in Article 11
of Regulation (EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU)
2017/2469.
This assessment concerns only risk that might be associated with consumption of the NF under the
proposed conditions of use and is not an assessment of the efficacy of 6′-Sialyllactose (6′-SL) sodium
salt with regard to any claimed benefit.
3. Assessment
3.1. Introduction
The NF primary constituent is the sodium salt of 6′-Sialyllactose, henceforth named ‘6′-SL sodium
salt’. The trisaccharide 6′-Sialyllactose (6′-SL) is composed of the monomers glucose, galactose and N-
acetylneuraminic acid (NANA, hereinafter also referred to as ‘sialic acid’). It is one of the most
abundant sialylated (acidic) oligosaccharides in the oligosaccharide fraction of human milk (HMOs –
human milk oligosaccharides). The 6′-SL in the NF is obtained by fermentation and is isolated as a
purified ingredient in the sodium salt form. The NF is intended to be used in foods for infants and
young children (including the use as human-identical milk oligosaccharides (HiMO) in infant formulae
(IF) and follow-on formulas), foods for special medical purposes, total diet replacements for weight
control, food supplements, beverages and a variety of other foods (e.g. dairy products, bakery wares).
The target population is the general population.
Other HiMOs, namely LNnT, 2’-FL, DFL and LNT produced by chemical synthesis or by fermentation
with derivatives of E. coli K-12, have been assessed previously (EFSA NDA Panel, 2015, 2019a,b).
The applicant indicated that according to Regulation (EU) 2015/2283, this NF falls under the
following categories:
i) ‘food with a new or intentionally modified molecular structure, where that structure was not
used as, or in, a food within the Union before 15 May 1997’; and
ii) ‘food consisting of, isolated from or produced from microorganisms, fungi or algae.’
3.2. Identity of the NF
The NF is a powdered mixture mainly composed of 6’-SL sodium salt, but also containing D-lactose,
sialic acid and a small fraction of other related saccharides resulting in a fully characterised mixture of
carbohydrates (> 99% in representative batches, see Table 1). It is produced by fermentation with a
genetically modified strain of Escherichia coli K12 DH1 MDO. The main component is the sodium salt of
Neu5Ac-(a2-6)-Gal-(b1-4)-Glc (6’-SL) in which sodium N-acetylneuraminate is linked through an a-(2-
6) bond to D-galactose and linked through a b-(1-4) bond to the reducing end D-glucose, which is in
equilibrium between the a- and b-anomeric forms. 6’-SL is a constitutional isomer of 3’-Sialyllactose,
which contains the same monosaccharide moieties, with the linkage between Neu5Ac and D-galactose
being a-(2-3) instead of a-(2-6).
6’-SL sodium salt is characterised by the molecular formula: C23H38NO19Na; molecular mass: 655.53
Da; CAS No 157574-76-0; IUPAC name: N-Acetyl-a-D-neuraminyl-(2?6)-b-D-galactopyranosyl-(1?4)-
D-glucose, sodium salt
The structure has been confirmed by monodimensional (1D) and two-dimensional (2D) 1H and 13C
Nuclear Magnetic Resonance spectroscopy (NMR). 1H NMR spectra show chemical shifts fully
corresponding to those reported in the literature for 6’-SL (Urashima et al., 2018), together with a
minor impurity (i.e. lactose). By Nuclear Overhauser Effect Spectroscopy (NOESY), some intra- and
inter-residual correlations were shown. All correlations for carbons involved in glycosidic linkages were
evidenced in the Hetero Single Quantum Coherence (HSQC) spectrum and the interglycosidic
correlations showing the positions of the glycosidic linkages were confirmed by the Heteronuclear
Multiple Bond Correlation (HMBC) spectrum. Taken together, NMR data confirm that the glycosidic
linkage between N-acetylneuraminic acid (Neu5Ac) C2 and the adjacent galactose (Gal H6 and H6’) is
a-(2-6). An inter-residual correlation was also observed between Gal H1 and Glc C4 in the HMBC
spectrum, this together with the coupling constants of the Gal H1 and Glc H1 signals are indicating the
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1-4 connection between the Gal and Glc units and that the pyranose configuration is b for the Gal unit
and that the reducing end glucose is in equilibrium between the a- and the b-anomeric forms. Also,
the mass fragmentation pattern of 6’-SL in MS/MS spectrometry has been provided and is consistent
with the structure proposed (Figure 1, from the dossier).
The 6’-SL produced by the microbial fermentation described has been shown to be chemically and
structurally identical to its naturally occurring counterpart present in human milk oligosaccharides by
mono- and two-dimensional NMR and is therefore considered as HiMO.
3.3. Production process
According to the data provided by the applicant, the NF is produced pursuant to Good Manufacturing
Practice (GMP) and Hazard Analysis Critical Control Points (HACCP) principles. The production process is
comparable to those of the already authorised HiMOs, such as LNnT (lacto-N-neotetraose), 2’-FL (2’-
Fucosyllactose), 2’-FL/DFL (difucosyllactose) and LNT (lacto-N-tetraose) also previously assessed by
EFSA (2’FL/DFL and LNT, EFSA NDA Panel, 2019a,b).
The manufacturing process can be broadly divided into two stages. In the first stage, D-lactose and
D-glucose are used for production of 6’-SL by the adapted cellular metabolism of the producing
microorganism, which uses D-glucose as an energy source and D-lactose as a substrate for 6’-SL
biosynthesis. At the end of the fermentation process, the production microorganism is entirely
removed from the medium by filtration. The second stage of the process includes several purification
steps after which the acidic 6’-SL solution is alkalised with NaOH with formation of the 6’-SL sodium
salt to obtain the NF as a dried powdered mixture.
The microorganism used in the fermentation process for the production of the NF is a genetically
modified derivative of the parental strain E. coli K-12 DH1 (F-ʎ-gyrA96 recA1 relA1 endA1 thi-1 hsdR17
supE44), that was obtained by the applicant from the German Collection of Microorganisms and Cell
cultures (DSMZ) and deposited under DSM No. 4235. The derivative producing strain has been
deposited in the DSMZ in Braunschweig, Germany.
The parental strain E. coli K-12 DH1 is derived from E. coli K-12 by forced random mutagenesis.
The whole genomes of E. coli K-12 and of other derivative strains, including E. coli K-12 DH1, were
sequenced and compared with other E. coli strains. The results indicate that E. coli K-12 and its
derivatives show genomic differences compared to pathogenic strains (Blattner et al., 1997;
Lukjancenko et al., 2010). Although the species E. coli was considered not suitable for qualified
presumption of safety (QPS) status (EFSA BIOHAZ Panel, 2018), E. coli K-12 is considered as a safe
and non-pathogenic or toxigenic microorganism widely used for biotechnological applications (Gorbach,
1978; OECD 1986; Muhldorfer and Hacker, 1994; U.S. EPA, 1997).
The applicant provided a detailed description of the genetic modification steps applied to the
parental strain E. coli K-12 DH1 to obtain the derivative strain used to produce the NF.
The absence of viable cells of the producing microorganism in the NF was demonstrated by testing
five batches of the NF for bacteria from the Enterobacteriaceae family according to internationally
recognised methods (ISO 21528-1:2004, MSZ ISO 21528-2:2007). The specification for
Enterobacteriaceae set at ‘absent in 10 g’ ensures absence in the final product of the microorganism,
since E. coli belongs to the Enterobacteriaceae family. Furthermore, the absence of residual proteins is
confirmed by an adaptation of the Bradford protein method, which has been developed to quantify
proteins down to 0.005 w/w% level. No residual protein was detected in the final method above the
0.01 w/w% specification.
In addition, no residual DNA from the production organism was detected in five independent
batches of the NF using three quantitative polymerase chain reaction (PCR) assays targeting short
subsequences of specific inserted genes as well as a short subsequence of the 23S rRNA subunit of
Figure 1: Structure of 6’-SL sodium salt
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E. coli. Upon EFSA’s request, the applicant provided data to demonstrate the validity of the method in
accordance to the EFSA guidance on microorganisms used as production organisms (EFSA FEEDAP
Panel, 2018).
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
The NF contains 6’-SL sodium salt as the primary ingredient (around 95% w/w dry matter as
sodium salt). The remainder is a mixture of substances including D-lactose, sialic acid, 6’-sialyl-
lactulose and other carbohydrates.
The Panel therefore notes that although the main component of the NF is 6’-SL sodium salt, other
fractions (lactose, sialic acid and 6’-sialyl-lactulose) are present in different amounts in the NF. Lactose
is the most prevalent molecule in human breast milk (approximately 7 g/100 mL). Sialic acid is an
endogenous human and ubiquitous nutritional monosaccharide (EFSA NDA Panel, 2017; R€ohrig et al.,
2017) while 6’-sialyl-lactulose is derived from 6’-SL by isomerisation of the terminal glucose moiety into
fructose mainly under alkaline conditions during the production process (Zeng et al., 2018). In
representative batches of the NF, the amount of lactose ranged between 2% and 3% while the
amount of each of the other two saccharides was below 1%.
With regard to the physicochemical properties, the NF can be described as white to off-white
amorphous powder or agglomerate. It is readily soluble in aqueous solutions (max. 500 mg/mL, 25°C).
The applicant provided results of batch-to-batch compositional analyses for five batches of the NF
(Table 1). 6’-SL and minor impurities have been analysed by high performance anion exchange
chromatography coupled to pulsed amperometric detection (HPAEC-PAD), using ‘in-house’ validated
methods as well as analysis by certified external international laboratories.
The microbiological purity of batches of the NF has been assessed for non-pathogenic
microorganisms (bacteria, yeasts and moulds) as general hygiene indicators, as well as for selected
food-borne pathogens.
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
Table 1: Batch-to-batch analysis for five batches of NF
Parameters
Batches
Mean  SDCPN5315
1000117 FD
CPN5315
1000317 FD
CPN5315
1000417 FD
CPN5315
1000617 FD
CPN5315
1000717 FD
Physicochemical properties
pH (20°C, 5%
solution)
5.4 5.2 5.3 5.6 5.8 5.5  0.2
Composition
HIMS (w/w % dry
matter)(a)
98.0 99.9 99.4 96.6 98.1 98.4  1.3
6’-SL sodium salt
(w/w % dry
matter)
94.3 96.8 97.1 93.9 95.3 95.5  1.4
D-Lactose [w/w %] 2.89 2.52 2.01 1.92 1.94 2.26  0.43
Sialic acid [w/w %] 0.68 0.51 0.33 0.81 0.85 0.64  0.22
6’-sialyl-lactulose
[w/w %]
0.54 0.75 0.76 0.65 0.72 0.68  0.09
Sum of other
carbohydrates
[w/w %]
0.56 0.55 0.42 0.63 0.66 0.56  0.08
Total
carbohydrates (dry
matter) [w/w %](b)
99.0 101.1 100.6 97.9 99.5 99.6  1.3
Water [w/w %] 0.38 0.44 0.42 0.44 0.47 0.43  0.03
Sodium [w/w %] 3.27 3.23 3.06 3.15 3.25 3.19  0.09
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3.4.1. Stability
Stability of NF
The bulk stability of the powdered NF produced by fermentation has been investigated in two
representative batches, in an ongoing 5-year study under real-time conditions (25°C, 60% relative
humidity (RH)) and an ongoing 2-year study under accelerated conditions (40°C, 75% RH). Results
were provided for both studies for 12 months.
Upon EFSA’s request for additional information, the applicant provided interim results of the same
two batches of the NF up to 24 months for both the real-time stability and accelerated stability
studies. Results on composition, sensory testing and microbiological parameters indicate that there is
no appreciable degradation of NF ingredients, no changes in impurity profile and no alterations in the
microbiological quality of the NF.
On the basis of these data and of the accelerated stability studies at 40°C, the reaction rate of
isomerisation was calculated and extrapolated by the Arrhenius analysis to 25°C (which is the
temperature of storage of the NF), indicating, according to the applicant, a shelf-life of 5 years for the NF.
In addition, results for stress stability studies for the NF have been provided by the applicant.
The NF in the solid state was heated in an oven at 80°C in ambient humidity for 28 days. The
results show that 6’-SL decreased (from 82.9% to 75.3%), lactose and sialic acid slightly increased,
while 6’-Sialyl-lactulose, not detected at time 0, increased up to 9.5%. At higher humidity, 6’-SL
remained steady for the first 2 days, then slightly decreased, while 6’-sialyl-lactulose increased up
to 11.4% at the end of the month.
Parameters
Batches
Mean  SDCPN5315
1000117 FD
CPN5315
1000317 FD
CPN5315
1000417 FD
CPN5315
1000617 FD
CPN5315
1000717 FD
Chloride by IC
[w/w %]
0.130 < 0.003 < 0.002 0.049 0.079 0.053  0.048
Residual proteins
(Bradford method)
[w/w %]
< LoR < LoR < LoR < LoR 0.0051
Microbiological parameters
Aerobic mesophilic
total plate count
[CFU/g]
< 10 < 10 < 10 < 10 < 10 < 10
Enterobacteriaceae
[in 10 g]
Absent Absent Absent Absent Absent Absent
Salmonella spp. [in
25 g]
Absent Absent Absent Absent Absent Absent
Cronobacter
(Enterobacter)
sakazakii [in 10 g]
Absent Absent Absent Absent Absent Absent
Listeria
monocytogenes [in
25 g]
Absent Absent Absent Absent Absent Absent
Bacillus cereus
[CFU/g]
< 10 < 10 < 10 < 10 < 10 < 10
Yeasts [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
Moulds [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
Residual
endotoxins
[EU/mg]
0.014 NA 0.340 0.100 0.840 0.32  0.32
HiMS: human identical milk saccharides, it includes 6’-SL sodium salt, D-lactose and sialic acid; CFU: colony forming units; 6’-SL:
6’-Sialyllactose; IC: ion chromatography;  SD: standard deviation; LoR (limit of reporting) 0.0050 w/w %; EU: endotoxin units;
NA: not available.
(a): Sum of 6’-SL sodium salt, lactose and sialic acid.
(b): Sum of all carbohydrates.
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Based on the data available, the Panel considers that the NF is expected to be stable for at least 24
months when stored at room temperature and low humidity in the solid state.
Stability of NF under the intended conditions of use
The NF was stable for a month in water solutions at neutral pH and 35°C while in acidic conditions (pH
3 at 35°C), it was almost completely hydrolysed to lactose and sialic acid. Under alkaline conditions (pH 9
at 35°C for a month), isomerisation of 6’-SL to 6’-sialyl-lactulose was observed (up to approximately
13%). Both degradation pathways were observed on amorphous 6’-SL freeze-dried from solutions with
different pHs by forced stability studies (at 60°C for 2 months and at 80°C for 1 month). The 6’-SL was
most stable when obtained from solutions at pH 5, where no significant hydrolysis was observed.
When oxidative stress was applied to a 6’-SL solution for one day, no degradation was observed
neither in the presence of 0.1% H2O2 nor in the presence of 0.1 M equivalent of ACVA (4,4’-azobis
(cyanovaleric acid)).
The stability of the NF in the powdered IF has been investigated following 12 months storage at
different temperatures (4–37°C) and the target concentration of 0.37 g/100 g (dry matter) was found
to be constant over time.
No other stability data for the NF in real food matrices have been provided. However, the applicant
made reference to studies conducted with other HiMS (human identical milk saccharides) (i.e. 2’-FL,
LNnT and sialic acid) in food matrices (e.g. yoghurt, ready-to-drink flavoured milk) where no significant
loss of the added HiMO has been observed. In its previous assessment for these HiMOs, the NDA
Panel concluded that ‘the data provide sufficient information with respect to the stability of the NF’
(EFSA NDA Panel, 2015, 2017).
The Panel considers that the available data provide sufficient information with respect to the
stability of the NF in the food matrices at neutral pH, when stored at room temperature under proper
storage conditions.
3.5. Specifications
The specifications of the NF as proposed by the applicant are presented in Table 2. The parameters
include the main components of the NF mixture of HiMS, predominantly 6’-SL sodium salt, D-lactose,
sialic acid and the isomer 6’-sialyl-lactulose. The sum of relevant HiMSs has been introduced by the
applicant as a parameter to ensure a highly consistent product quality. The 6’-SL sodium salt content is
specifically set at a minimum of 90 w/w % (dry matter).
Another parameter called ‘sum of other carbohydrates’ has been introduced, to include other
carbohydrates individually present in low concentrations, up to a total amount of 3% w/w.
Microbiological parameters for Listeria monocytogenes, Cronobacter (Enterobacter) sakazakii and
Bacillus cereus are monitored using internal specifications.
Analyses were performed using internationally recognised methods or newly developed and
validated analytical protocols at Glycom’s Research & Development Department and confirmed by
accredited laboratories.
The Panel considers that the information provided on the specification of the NF is sufficient.
Table 2: Specifications of the NF
Description: 6’-Sialyllactose sodium salt (6’-SL sodium salt) is a purified, white to off-white powder or
agglomerates that is produced by a microbial process and contains limited levels of lactose and sialic acid
Source: A genetically modified strain of Escherichia coli K-12 DH1 MDO
Parameter Specification Method
Sum of HiMS(a) (w/w % dry matter) ≥ 94.0 HPAEC/PAD
6’-SL sodium salt (w/w % dry matter) ≥ 90.0 HPAEC/PAD
D-Lactose [w/w %] ≤ 5.0 HPAEC/PAD
Sialic acid [w/w %] ≤ 2.0 HPAEC/PAD
6’-sialyl-lactulose [w/w %] ≤ 3.0 HPAEC/PAD
Sum of other carbohydrates [w/w %] ≤ 3.0 HPAEC/PAD
pH (20°C, 5% solution) 4.5–6.0 Eur. Ph. 9.2 2.2.3 (07/2016:20203)
Water [w/w %] ≤ 6.0 Karl-Fisher
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3.6. History of use of the NF and of its source
3.6.1. History of use of the NF
The NF does not have a history of use.
6’-SL has been detected in domestic farm animal milk, albeit at lower concentrations as compared to
human milk. Oligosaccharides in bovine milk are 20 times less concentrated than in human milk; however,
sialylated oligosaccharides accounted for approximately up to 80% of the total oligosaccharide pools. The
amount of 6’-SL in bovine milk is estimated to be ranging from 4 to 10 mg/L and up to 100 mg/L in
colostrum (Aldredge et al., 2013; Urashima et al., 2013; Albrecht et al., 2014), more than 50 times lower
than human breast milk levels.
3.6.2. Consumption of oligosaccharides constituent of the NF in breast milk
Human breast milk contains a family of structurally related oligosaccharides, known as HMOs and
representing the third largest fraction of solid components. The highest concentrations of HMOs occur
in human colostrum (20–25 g/L), and concentrations between 5 and 20 g/L occur in mature human
milk (Thurl et al., 2010; Bode, 2012; Urashima et al., 2018). HMOs’ concentration and composition
vary across mothers and over the course of lactation. 6’-SL belongs to the subfraction of ‘acidic’ HMOs,
which is characterised by the presence of sialic acids, and the whole subfraction accounts for 1.5–3.3
g/L (Thurl et al., 2010; Rijnierse et al., 2011; Bode, 2012). 6’-SL is the predominant acidic HMO and
one of the most abundant HMOs along with 2’-FL, lacto-N-fucopentaose I, LNT and LNnT.
There are two naturally occurring sialyllactoses, which are constitutional isomers with a minimal
structural difference: the oligosaccharide backbone can be sialylated by a-(2-3) or a-(2-6) linkages,
resulting in 3’-SL or 6’-SL, respectively. The two forms have been shown to have similar functions and
biological roles (Tarr et al., 2015).
Several publications on HMOs and 6’-SL in human milk have been provided by the applicant.
The highest concentration of 6’-SL and other HMOs in human milk is reported in colostrum, and the
concentration is depending on the stage of lactation (Asakuma et al., 2008; Austin et al., 2016; Coppa
et al., 1999, 2011; Kunz et al., 2017; McGuire et al., 2017; Spevacek et al., 2015; Thurl et al., 2010,
2017). Thurl et al. (2017) summarised the findings from 21 studies and reported that the content of
6’-SL in milk from mothers who delivered at term ranged from 0.38 to 0.91 g/L (average 0.64 g/L). It
was noted that the range of 6’-SL was slightly wider (ranging from 0.25 to 1.08 g/L, average 0.66 g/L)
in mothers who delivered preterm.
Based on the mean and the highest reported occurrence levels of 6’-SL in human milk from
mothers who had a preterm delivery, as reported by Thurl et al. (2017), and considering the average
and high daily intake of breast milk (800 mL and 1,200 mL, respectively) for infants from 0 to 6
months (EFSA NDA Panel, 2013), the daily intake levels of 6’-SL from human milk for a 6.7 kg body
weight (bw) infant (EFSA Scientific Committee, 2012) have been calculated (Table 3). This default
Sodium [w/w %] 2.5–4.5 EN 13805:2002; EPA-6010C:2007
Chloride by IC [w/w %] ≤ 1.0 ISO10304-2:1999
Residual protein [w/w %] ≤ 0.01 Bradford assay (UV spectroscopy)(b)
Microbiological Parameters
Aerobic mesophilic total plate count ≤ 1,000 CFU/g ISO 4833-1:2014
Enterobacteriaceae ≤ 10 CFU/g ISO 21528-1:2004, ISO 21528-2:2007
Salmonella spp. Absent in 25 g ISO 6579:2006
Yeasts ≤ 100 CFU/g ISO 21527-2:2008
Moulds ≤ 100 CFU/g ISO 21527-2:2008
Residual endotoxins ≤ 10 EU/mg Eur. Ph. 2.6.14
6’-SL sodium salt: 6’-Sialyllactose sodium salt; CFU: colony-forming units; EU: endotoxin units; Eur. Ph.: European
Pharmacopoeia; HiMO: human-identical milk oligosaccharides; HPLC: high-performance liquid chromatography; IC: ion
chromatography; CAD: charged aerosol detection; PAD: pulsed amperometric detection; HPAEC: high performance anion
exchange chromatography; KF: Karl-Fischer; RT: retention time; ISO: international organization for standardization; UV:
ultraviolet.
(a): Sum of HiMS: 6’-SL sodium salt, D-lactose and sialic acid.
(b): LOR (limit of reporting) = 17 mg/kg.
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body weight used by the NDA Panel is for an infant of 3–6 months of age, who is more likely than
younger infants to consume these volumes of human milk.
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population proposed by the applicant is the general population.
3.7.2. Proposed uses and use levels
The NF is intended to be added to a variety of foods, at the maximum use levels as indicated in
Table 4. The Panel notes that for the category ‘Food for special medical purposes’, the applicant did
not propose maximum use levels or maximum intake levels.
The applicant also intends to market the NF as a food supplement, at the maximum daily intake of
1 g for individuals above 3 years of age or at a maximum level of 0.4 or 0.3 g/day when intended for
infants (up to 11 months) or young children (12–35 months), respectively.
Food supplements are not intended to be used if other foods with added NF or breast milk are
consumed on the same day.
Table 3: Estimated daily intake levels of 6’-SL from human milk (800 and 1,200 mL) for infants of
6.7 kg bw, based on mean and high concentration of 0.66 and 1.08 g/L, respectively, of
6’-SL measured in human milk from mothers who had a preterm delivery (Thurl et al., 2017)
Daily intake levels (mg/kg bw) from 800 mL
of human milk
Daily intake levels (mg/kg bw) from
1,200 mL of human milk
Mean concentration High concentration Mean concentration High concentration
6’-SL 79 129 118 193
bw: body weight.
Table 4: Proposed food uses and maximum use levels of the 6’-SL
EU food
category
number
Food category name Proposed Maximum use level
1 Dairy products and analogues
1.1 Unflavoured pasteurised and unflavoured
sterilised (including UHT) milk
0.5 g/L
1.2/1.3 Unflavoured fermented milk-based products 0.5 g/L beverages
2.5 g/kg for products other than beverages
1.4 Flavoured fermented milk-based products
including heat-treated products
0.5 g/L beverages
5 g/kg for products other than beverages
7 Bakery wares
7.2 Fine bakery wares. Cereal bars only 5 g/kg
13 Foods for Special Groups (FSG)
13.1 Foods for infants and young children
13.1.1 Infant formula as defined in Regulation (EU) No
609/2013
0.4 g/L in the final product ready for use,
marketed as such or reconstituted as
instructed by the manufacturer
13.1.2 Follow-on formula as defined in Regulation (EU)
No 609/2013
0.3 g/L in the final product ready for use,
marketed as such or reconstituted as
instructed by the manufacturer
13.1.3 Processed cereal-based food and baby food for
infants and young children as defined in
Regulation (EU) No 609/2013
0.3 g/L in the final product ready for use,
marketed as such or reconstituted as
instructed by the manufacturer
2.5 g/kg for products other than beverages
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3.7.3. Anticipated intake of the NF
Anticipated intake of the NF from the consumption of infant formula in infants up to
16 weeks of age
IF is expected to be the only food consumed by infants aged 0–16 weeks who are not breastfed. A
high consumption of IF has been estimated to be 260 mL/kg bw per day for infants aged 0–16 weeks
(EFSA Scientific Committee, 2017). Based on the maximum proposed use level of the NF (0.4 g/L in
IF), the high intake of the NF from IF alone is estimated for an infant of 6.7 kg to be 104 mg/kg bw
per day.
The Panel notes that the anticipated daily intake of the NF from the consumption of IF (only) does
not exceed the estimated high daily intake of 6’-SL in breast-fed infants per kg/bw (Table 3).
Anticipated intake of 6’-SL from the proposed uses and use levels of the NF
The applicant estimated the daily intake of the NF by using the EFSA Food Additive Intake model
(FAIM) tool (FAIM 2.0, 2017) and compared the intake to surveys conducted in the UK (NDNS
(National Diet and Nutrition Survey) and its complement DNSIYC (Diet and Nutrition Survey of Infants
and Young Children)). However, considering that the food categories in the FAIM tool, which are based
on Regulation (EC) No 1333/20083, do not allow a precise matching with the food categories proposed
for the NF, EFSA performed an assessment of the anticipated daily intake of the NF, at the maximum
proposed use levels of the NF, using individual data from EU dietary surveys (EFSA, 2011) and by
applying the FoodEx2 classification (Table 5). The range of mean and 95th percentile anticipated daily
intake of the NF for all subjects, among the EU dietary surveys, is presented in Table 6.
The refined anticipated daily intake of the NF for each population group from each EU dietary
survey is available in the excel file annexed to this scientific opinion (it can be found in the online
version of this output under ‘Supporting information’: https://doi.org/10.2903/j.efsa.2020.6097).
EU food
category
number
Food category name Proposed Maximum use level
13.1.4 Milk-based drinks and similar products intended
for young children
0.3 g/L in the final product ready for use,
marketed as such or reconstituted as
instructed by the manufacturer
2.5 g/kg for products other than beverages
13.2 Foods for special medical purposes as defined in Regulation (EU) No 609/2013
13.2 Foods for special medical purposes as defined in
Regulation (EU) No 609/2013
On case-by-case basis
13.3 Total diet replacement for weight control as defined in Regulation (EU)
No 609/2013
13.3 Total diet replacement for weight control as
defined in Regulation (EU) No 609/2013
1.0 g/L beverages
10 g/kg for products other than beverages
14 Beverages
14.1.4 Flavoured drinks (excluding cola-type drinks) 0.5 g/L
UHT: ultra-high temperature.
3 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives (Text
with EEA relevance) OJ L 354, 31.12.2008, p. 16–33.
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Table 5: FoodEx2 categories and maximum use levels of the NF used in the refined estimate of the
anticipated daily intake of the NF using individual data from EU dietary surveys
CODE
FoodEx2
level
Food category
Maximum use level of
the NF mg/100 g
A02LV 5 Cow milk 50
A0CXA 5 European buffalo milk 50
A02MC 5 Sheep milk 50
A02MB 4 Goat milk 50
A02MV 3 Butter milk 50
A02NQ 4 Yoghurt drinks 50
A02NR 4 Probiotic milk-like drinks 50
A02NV 5 Kefir 50
A02NE 4 Yoghurt 250
A00EY 4 Cereal bars 500
A00EZ 4 Cereal bars plain 500
A00FA 4 Cereal bars mixed 500
A03PZ 4 Infant formulae, powder 325
A03QE 4 Infant formulae, liquid 40
A03QK 4 Follow-on formulae, powder 242.5
A03QQ 4 Follow-on formulae, liquid 30
A03QZ 3 Cereals with an added high protein food which have to be
reconstituted
150
A03QY 3 Simple cereals which have to be reconstituted 150
A0BZF 3 Cereals with added high protein food reconstituted 30
A0BZE 3 Simple cereals for infants and children reconstituted 30
A03RA 3 Biscuits, rusks and cookies for children 250
A03RC 2 Ready-to-eat meal for infants and young children 250
A03RB 3 Pasta for children 250
A03RN 3 Fruit and vegetable juices and nectars specific for infants
and young children
30
A03RP 3 Special food for children’s growth 30
A03RT 4 Total daily diet replacement for weight reduction 1,000
A0EQN 5 Soft drinks with minor amounts of fruits or flavours 50
A03EA 5 Soft drink with fruit juice (fruit content below the minimum
for nectars)
50
A03EX 5 Soft drink, flavoured, no fruit 50
Table 6: Ranges among EU surveys of the estimated daily intake of the NF (mg/kg bw), based on
the individual food intake data from the EFSA Comprehensive Food Consumption Database
Age groups
Number of
EU dietary
surveys
Estimated daily intake of the NF – all subjects (mg/kg bw)
Range of means (lowest and
highest) among EU dietary
surveys
Range of 95th percentile (lowest
and highest) among EU dietary
surveys
Infants (up to 11
months)
11 16–74 38–192
Young children or
toddlers (12–35
months)
14 15–46 39–147
Other children (3–9
years)
19 6–25 16–61
Adolescents (10–17
years)
18 3–8 7–19
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The Panel notes that the highest estimated 95th percentile intake (i.e. 192 mg/kg bw) on the basis
of 11 dietary surveys covered by the EFSA Food Consumption Database is similar to the high estimate
for 6’-SL from human milk (i.e. 193 mg/kg bw, Table 3) in infants.
Considering the conservative assumption underlying this type of intake assessment, in particular,
assuming that all foods of the proposed food categories consumed by infants contain the NF at the
maximum proposed use levels, the Panel considers very unlikely that even the most exposed
population category (infants up to 11 months) would exceed the high intake level estimated for 6’-SL
intake from human milk.
Anticipated intake of 6’-SL from food supplements
The applicant has proposed a maximum daily intake of 1 g of the NF as food supplements for
individuals above 3 years of age or at a maximum level of 0.4 or 0.3 g/day when intended for infants
(up to 11 months) or young children (12–35 months), respectively. Food supplements are not intended
to be used if other foods with added 6’-SL sodium salt are consumed on the same day. For infants and
young children, food supplements are not intended to be used if breast milk or other foods with added
NF are consumed on the same day.
The maximum daily intake from food supplements of the NF (i.e. 1 g/day) results in a maximum
daily intake ranging from 14 to 43 mg/kg bw in the general population. The maximum dose of 0.4 g/
day in infants (bw of 6.7 kg) and 0.3 g/day in young children (bw of 11.9 kg) results in a maximum
intake of 60 or 25 mg/kg bw, respectively (default body weight values from EFSA Scientific Committee
(2012)).
The Panel notes that the maximum daily intake of 6’-SL from the use of NF as food supplement
(i.e. from 300 mg to 1 g/day) for any population category does not exceed the estimated high daily
intake of 6’-SL from human milk calculated for infants on a body weight basis (Table 3).
3.7.4. Combined intake from the NF and other sources
The Panel notes that the NF is not authorised for use in food categories other than those proposed
for the NF under assessment. Therefore, the only relevant additional source for these oligosaccharides
is human milk.
Food supplements are not intended to be used if other foods with added NF or breast milk are
consumed on the same day.
3.8. Absorption, distribution, metabolism and excretion (ADME)
There are no data submitted for the NF.
HMOs, including 6’-SL, are considered ‘non-digestible oligosaccharides’ (EFSA NDA Panel, 2014) since
they do not undergo any significant digestion in the upper gastrointestinal tract (Brand-Miller et al.,
1995, 1998; Engfer et al., 2000; Gnoth et al., 2000; Chaturvedi et al., 2001; Rudloff and Kunz, 2012).
Brand-Miller et al. (1995, 1998) reported that HMOs, consumed as a load (a purified oligosaccharide
fraction from human milk), are fermented in the colon by intestinal microbiota. Chaturvedi et al. (2001)
and Coppa et al. (2001) reported that 97% and 40–50%, respectively, of the ingested HMOs are
excreted unchanged in faeces of breastfed infants. Furthermore, approximately 1–2% of the ingested
amounts of HMOs is excreted unchanged in the infants’ urine (Rudloff et al., 1996; Goehring et al.,
2014; Kunz et al., 2017, EFSA NDA Panel, 2019a,b).
In a paper from Goehring et al. (2014), concentrations of 6’-SL were measured in breast milk and
plasma and urine of breastfed infants. Concentrations in breast milk measured were within the
Age groups
Number of
EU dietary
surveys
Estimated daily intake of the NF – all subjects (mg/kg bw)
Range of means (lowest and
highest) among EU dietary
surveys
Range of 95th percentile (lowest
and highest) among EU dietary
surveys
Adults (18–64 years) 19 1–5 5–13
Elderly (≥ 65 years) 18 1–4 5–10
Pregnant women 2 1–5 4–11
Lactating women 2 4-5 10–11
bw: body weight.
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expected range (mean of 0.72 g/L) and urinary excretion was accounting for approximately 4% of the
intake from breast milk. However, there was no clear correlation between urinary and milk
concentrations and the analytical method used was unable to detect 6’-SL in plasma.
It has been observed that an infant, who is breastfed, may receive up to 150 mg of individual
oligosaccharides from each feed and that an amount up to 3 mg per day is found in the urine (Rudloff
and Kunz, 2012; Rudloff et al., 2012). Specifically, for 6’-SL (and few other HMOs), it has been
demonstrated that absorption and urinary excretion are also occurring in the rat (Vazquez et al.,
2017).
Based on information available on HMOs, the Panel considers that limited digestion of the NF occurs
in the upper gastrointestinal tract and that only small amounts are expected to be absorbed. Moreover,
there are no indications that the absorption of 6’-SL or other components of the NF may differ from
that of similar components in human milk.
3.9. Nutritional information
The NF is mainly composed of the non-digestible oligosaccharide 6’-SL (EFSA NDA Panel, 2014).
The Panel considers that consumption of the NF at the proposed use levels is not nutritionally
disadvantageous.
The Panel notes that the NF, being a sodium salt, may contribute to the daily sodium intake.
In its Opinion on DRVs for sodium, the NDA Panel has provided advice on levels of sodium intake
that are considered safe and adequate4 for population groups aged 1 year and older (EFSA NDA Panel,
2019c). Considering the maximum sodium content in the NF of 4.5%, the intake of sodium from the
NF is expected to represent up to 7% (up to 79 mg sodium/day) of the sodium intake of 1.1 g/day
considered as safe and adequate for toddlers (1–3 years). For other children and adults, the intake of
sodium from the NF can represent up to 5% of the sodium intake levels considered as safe and
adequate for these age groups.
As for infants up to the age of 6 months consuming IF, the maximum sodium intake from the NF
would be approximately 31 mg per day considering a daily intake of IF of 260 mL/kg. This corresponds
to about 25% of the daily sodium intake of exclusively breast-fed infants (120 mg sodium/day during
the first 6 months; EFSA NDA Panel, 2019c).
For older infants aged 7–11 months, the Panel established an adequate intake (AI)5 of 200 mg/day
(EFSA NDA Panel, 2019c). In this age group, the maximum sodium intake from the NF is estimated to
be 76 mg sodium/day, which corresponds to 38% of the AI.
3.10. Toxicological information
The list of toxicological studies, which were provided and claimed proprietary by the applicant, is
reported in Table 7. These studies were conducted with the NF (batch CPN53151000317 FD), which
was constituted by 96.8% w/w dry matter of 6’-SL sodium salt (with a total of 99.9% dry matter of
HiMSs).
The applicant also provided information on toxicological studies conducted with enzymatically
produced 6’-SL (Gurung et al., 2018) and the Panel considers that these toxicological studies can
provide supporting evidence for the safety assessment of the NF (see Section 3.10.3). The Panel noted
that toxicological studies were also conducted with 3’-SL, the constitutional isomer of 6’-SL, which was
obtained by microbial fermentation using genetically modified strains of E. coli K-12.
4 These levels of sodium intake are called ‘safe’ because it takes account of the evidence describing the relationship between
sodium intake and CVD risk in the general population and ‘adequate’ in line with the definition of an Adequate Intake.
5 An Adequate Intake (AI) is the value set when there is not enough data to calculate an average requirement for a nutrient. An
AI is the average level of intake of a nutrient, based on observations or experiments that is assumed to be adequate.
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The Panel also noted that under acidic conditions, the NF will be hydrolysed to lactose and sialic
acid. The amount of sialic acid potentially formed (at the maximum level and intake, i.e. for infants at
95th percentile (Table 6), would result in 3.8 mg/kg bw), which is lower than the intake based on
natural levels in human milk (that is 11 mg/kg bw (EFSA NDA Panel, 2017)). Under alkaline conditions,
6’-sialyl-lactulose would also be formed although the content would remain very low (up to 5.8 mg/kg
bw) and is considered not having any laxative effect (suggested use in infants to treat constipation is
2.5 mL syrup/day corresponding to approximately 1.65 g lactulose/day).
3.10.1. Genotoxicity
The potential genotoxicity of the NF was investigated in a bacterial reverse mutation test and an
in vitro mammalian cell micronucleus test (Unpublished study report, 2018a). These studies were
conducted in compliance with Organisation for Economic Co-operation and Development (OECD)
principles of Good Laboratory Practice (GLP) (OECD, 1998a) and in accordance with the OECD test
guidelines No 471 and 487 of 1997 and 2016, respectively.
The in vitro assessment of the mutagenic potential of the NF was performed with histidine-
dependent auxotrophic mutants of Salmonella typhimurium, strains TA1535, TA1537, TA98 and TA100,
and a tryptophan-dependent mutant of Escherichia coli, strain WP2 uvrA (pKM101), that were exposed
to the NF diluted in water at concentrations up to 5,000 lg/plate either in the presence or absence of
liver microsomal fractions (S9). No substantial, reproducible or dose-related increases in revertant
colony numbers over control counts were observed with any of the strains following exposure to the
NF at any concentration (irrespective of the presence or absence of S9). No evidence of toxicity was
obtained following exposure to the NF. Therefore, the NF was shown to be non-mutagenic at
concentrations up to 5,000 lg/plate, in the absence or presence of metabolic activation.
In the in vitro mammalian cell micronucleus test, concentrations of 6’-SL sodium salt up to 2,000
lg/mL were tested to assess the potential of the NF to cause an increase in the induction of
micronuclei in in vitro cultured human peripheral blood lymphocytes in the presence or absence of
metabolic activation (S9 fraction). No statistically significant increases in the number of binucleate cells
containing micronuclei both after 3-h treatment in the presence of S9 mix or following 20-h treatment
in the absence of S9 were recorded. The NF did not show any evidence of clastogenicity or
aneugenicity in the absence and presence of metabolic activation.
Based on the results of these studies, the Panel considers that there are no concerns regarding
genotoxicity of the NF.
3.10.2. Repeated dose toxicity studies
The applicant provided a 14-day repeated dose oral toxicity study where groups of eight Crl:CD(SD)
neonatal rats/sex were given water (control), 4,000 and 5,000 mg/kg bw per day of NF expressed as
6’-SL sodium salt by oral gavage starting from day 7 of age (Unpublished study report, 2018c). There
were no deaths or any variations in clinical signs, body weight or macroscopic pathology attributable to
the NF. Clinical pathology parameters were not assessed.
In a 90-day study, groups of 10 Crl:CD(SD) neonatal rats/sex were given water (control), 1,000,
3,000 or 5,000 mg/kg bw per day of NF expressed as 6’-SL sodium salt by oral gavage starting from
7 days of age once daily for at least 90 days, until the day before necropsy (Unpublished study report,
2018d). An additional control group was treated with oligofructose powder (a non-digestible
oligosaccharide permitted in infant nutrition) at 5,000 mg/kg per day, to compare any effects related
Table 7: List of toxicological studies with the NF provided by the applicant
Test material Reference Type of study
NF (96.8% w/w dry
matter 6’-SL sodium salt)
Unpublished study report (2018a) Bacterial reverse mutation test (Ames test)
Unpublished study report (2018b) In vitro mammalian Cell Micronucleus Test
Unpublished study report (2018c) 14-day DRF repeated dose oral toxicity study in
neonatal rats
Unpublished study report (2018d) 90-day GLP repeated dose oral toxicity study in
neonatal rats
DRF: dose range finding.
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to the general fibre-like characteristics at the same high dose. Five additional rats/sex for control
groups and high dose of NF were observed over a 4-week recovery period.
This study has been designed based upon the OECD TG408 (OECD, 1998b), but has been adapted
(i.e. use of juvenile animals) to consider the requirements for toxicity testing of new chemical entities
for use in the paediatric population (as was suggested by US FDA, 2006 and EMEA, 2008). There were
no test item-related deaths or any variations in clinical signs attributable to the NF.
Statistically significant changes were observed in several parameters (summary results can be found
in the online version of this output under ‘Supporting information’: https://doi.org/10.2903/j.efsa.2020.
6097). However, the findings observed were of low magnitude, often without dose correlation,
sometimes occurring only in one gender or at the end of recovery period and are considered by the
Panel as overall not biologically relevant. The Panel also notes that this specific experimental design, with
treatment of animals by gavage prior to weaning, may result in high variability in several parameters.
At the microscopic examination, four rats receiving the highest dose showed small and soft testis
characterised by severe unilateral tubular atrophy and absence of sperm in the epididymis. Three of
the four rats affected were from the same litter and only one testis was affected in each animal. There
was no clear explanation for the observation. In the absence of such explanation, the author of the
study considered the intermediate dose of 3,000 mg/kg bw per day of the 6’-SL sodium salt as the
NOAEL (No Observed Adverse Effect Level). The Panel agrees with this conclusion.
3.10.3. Toxicological studies conducted with 6’-SL enzymatically synthetised
The applicant reported that in studies conducted following ‘Toxicological Principles for the Safety
Assessment of Food Ingredients’ (FDA ‘Redbook 2000’) and in accordance with GLP principles, 6’-SL
enzymatically produced (purity > 98%) did not elicit adverse effects in any of the tested doses or
concentrations. No signs of mutagenicity, clastogenicity or aneugenicity in genotoxicity studies
(bacterial mutation assay, chromosomal aberrations assay and in vivo micronucleus) were noted. In
the 90-day oral study in the rat (weaned rats of standard age), the highest dose of 5,000 mg/kg bw
per day was identified as an NOAEL. The authors concluded that ‘The 6’-SL sodium salt showed
toxicity profiles comparable to other carbohydrates and HMOs’ (Gurung et al., 2018).
The Panel considers the information on 6’-SL when produced by enzymatic synthesis as supportive
for the assessment of the NF.
3.10.4. Human data
No human intervention studies with 6’-SL have been provided by the applicant and no reference to
human data was made.
3.11. Allergenicity
The protein content in the NF is low as indicated in the specifications (Table 2).
In addition, the applicant has assessed the allergenic potential of introduced proteins as a result of
the genetic modification of the E. coli K-12 host (which itself is recognised as non-allergenic) using the
Table 8: List of toxicological studies conducted with 6’-SL produced by enzymatic synthesis
Test material Reference Type of study Experimental details
6’-SL (> 98%) Gurung et al. (2018) Bacterial Reverse Mutation Test 100, 300, 625, 1,250, 2,500 and
5,000 lg 6’-SL plate;  S9
In vitro chromosome
aberration test (CHL)
225, 450, and 900 lg 6’-SL/mL;  S9
In vivo mammalian Cell
Micronucleus Test
500, 1,000 and 2,000 mg 6’-SL/kg bw
Acute Toxicity Study in the SD
Rat
5 SD rats/sex per group; 5,000, 10,000,
15,000 and 20,000 mg 6’-SL/kg bw per
day
90-day GLP repeated dose oral
toxicity study in the SD rat
10 SD rats/sex per group; 1,000, 2,500,
5,000 mg 6’-SL/kg bw per day
CHL: Chinese hamster lung; SD: Sprague–Dawley.
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search algorithms provided by the Allergen Online tool (version 17) of the University of Nebraska
(FARRP, 2017). No sequence alerts for potential allergenicity were identified.
The Panel considers that the likelihood of allergenic reactions to the NF is low.
4. Discussion
The NF is mainly constituted of the sodium salt of a HiMO, 6’-SL, and other minor fractions (e.g.
sialic acid and 6’-sialyl-lactulose). The NF is obtained by microbial fermentation with a genetically
modified strain of E. coli K-12 DH1 MDO. The information provided on the manufacturing process,
composition and specifications of the NF, including the absence of DNA from the producing
microorganisms, does not raise safety concerns.
The applicant intends to add the NF to a variety of foods, including IF and follow-on formula, foods
for infants and young children, foods for special medical purposes and food supplements. The target
population is the general population.
The Panel notes that under acidic conditions, the NF will be hydrolysed to lactose and sialic acid
and it will not meet the specifications. The same would apply for 6-sialyl-lactulose formed under
alkaline conditions.
The Panel considers that there are no concerns regarding genotoxicity of the NF. In the 90-day oral
toxicity study conducted in neonatal rats at the doses of 1,000, 3,000 or 5,000 mg/kg bw per day of
the NF a testicular finding (monolateral tubular atrophy) has been observed at the high dose of 5,000
mg/kg bw per day. The Panel agrees with the authors’ conclusion identifying the dose of 3,000 mg/kg
bw as the NOAEL. When comparing the NOAEL from the 90-day toxicity study (3,000 mg/kg bw) with
the highest estimated exposure per population category (at 95th percentile; Table 6), the margins of
exposure are relatively low, with range from 16 to 300.
Considering that 6’-SL is a naturally occurring oligosaccharide present in human milk, the history of
human exposure to 6’-SL concerns breast-fed infants. 6’-SL is one of the most abundant acidic HMO
and one of the most represented HMOs along with 2’-FL, LNT, lacto-N-fucopentaose I, disiallylacto-N-
tetraose and LNnT in human milk. The Panel also notes that other HiMOs (2’-FL, DFL and LNT)
produced by fermentation with the same genetically modified E. coli strain have been recently
assessed (EFSA NDA Panel, 2019a,b).
The Panel notes that the anticipated daily intake of 6’-SL in the NF from the consumption of IF
only, in infants up to 16 weeks of age, does not exceed the highest intake level of 6’-SL in breastfed
infants on a body weight basis. The anticipated daily intake of the NF for the proposed uses at their
respective maximum use levels in the other population categories is not exceeding the highest intake
level of 6’-SL in breastfed infants on a body weight basis. Thus, since the intake in breastfed infants on
a body weight basis is expected to be safe also for other population groups, the Panel considers that
the intake of the NF for the proposed uses at their respective maximum use levels can be considered
safe. The maximum daily intake of 6’-SL as a food supplement at the proposed maximum levels (i.e.
from 300 mg to 1 g/day) for the respective population categories also does not exceed the highest
intake level of 6’-SL in breastfed infants per kg bw. Food supplements are not intended to be used if
other foods with added 6’-SL (as well as breast milk for infants and young children) are consumed on
the same day.
In terms of foods for special medical purposes, the applicant did not propose maximum use levels
and the Panel considers that the maximum use levels of the NF should not lead to higher daily intakes
than those estimated on the basis of the maximum levels specified for the proposed food uses or the
maximum daily intake proposed for food supplements.
It is finally noted that, as with other oligosaccharides, which are natural components of human
milk, the safety assessment is mainly based on the comparison between the natural intake in breastfed
infants and the estimated intake as NF. The same considerations apply for lactose and other mono-
and oligosaccharides (e.g. sialic acid) that are present as a very small fraction in the NF and
considered of no safety concern. 6’-sialyl-lactulose that is not a natural milk component is
characterised by very low concentrations not having any laxative effect.
5. Conclusions
The Panel concludes that the NF, composed of 6’-SL sodium salt and other structurally related
mono- and oligosaccharides, is safe under the proposed conditions of use, including the use as a food
supplement. The target population is the general population.
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Food supplements are not intended to be used if other foods with added NF or breast milk are
consumed on the same day.
The Panel could not have reached the conclusions on the safety of the NF under the proposed
conditions of use without the following data claimed as proprietary by the applicant:
• annexes to the dossier which relate to the identity, the production process, composition and
specifications of the NF (see annexes indicated in Section 2.1).
• bacterial reverse mutation test (Unpublished study report, 2018a), in vitro micronucleus test
(Unpublished study report, 2018b) and 90-day oral toxicity study with the NF (Unpublished
study report, 2018d) including the summary table of the statistically significant observations in
the 90-day study (Appendix B.3 to the dossier).
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of 6’-SL sodium salt as a novel food. Ref. Ares
(2019)3216553, dated 16/05/2019.
2) On 16/05/2019, a valid application from the European Commission on 6’-SL as NF, which
was submitted by Glycom A/S, was made available to EFSA by the European Commission
through Commission e-submission portal (NF 2019/0881) and the scientific evaluation
procedure started.
3) On 12/09/2019 and on 16/12/2019, EFSA requested the applicant to provide additional
information to accompany the application and the scientific evaluation was suspended.
4) On 02/12/2019 and 20/01/2020, additional information was provided by the applicant and
the scientific evaluation was restarted.
5) During its meeting on 23/03/2020, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of 6’-SL sodium salt as a NF pursuant to Regulation (EU)
2015/2283.
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Abbreviations
2’-FL 2’-Fucosyllactose
3’-SL 3’-Sialyllactose
6’-SL 6’-Sialyllactose
ACVA 4,4’-azobis (cyanovaleric acid)
ADME absorption, distribution, metabolism and excretion
bw body weight
CAD charged aerosol detection
CFU colony forming units
Da Daltons
DFL difucosyllactose
DSMZ German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung
von Mikroorganismen und Zellkulturen)
EMEA European Medicines Agency
EU endotoxin units
Eur.Ph. European pharmacopeia
FAIM Food Additive Intake Model
FDA US Food and Drug Administration
Gal Galactose
Glc glucose
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Points
HiMS human identical milk saccharides
HiMO human identical milk oligosaccharide
HMO human milk oligosaccharide
HPAEC high performance anion exchange chromatography
HPLC/CAD high performance liquid chromatography/charged aerosol detection
HMBC heteronuclear multiple bond correlation
HSQC heteronuclear single quantum coherence
IC Ion chromatography
IF infant formula
ISO International Organization for Standardization
K-F Karl Fischer
LNT lacto-N-tetraose
LNnT lacto-N-neotetraose
LOR limit of reporting
MS mass spectrometry
NANA N acetyl neuraminic acid
NDA The EFSA Panel on Nutrition, Novel Foods and Food Allergens
NDNS National Diet and Nutrition Survey
Neu5Ac N-acetylneuraminic acid
NF novel food
NMR nuclear magnetic resonance spectroscopy
NOAEL no observed adverse effect level
NOESY Nuclear Overhauser Effect Spectroscopy
NMR nuclear magnetic resonance spectroscopy
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OECD Organisation for Economic Co-operation and Development
PAD pulsed amperometric detection
PCR Polymerase chain reaction
QPS qualified presumption of safety
RH relative humidity
RT retention time
UHT Ultra-high temperature
UV ultraviolet
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